Insights on Cannabinoid Exposure in Substance Use Disorders
This 2026 review on cannabinoid exposure substance use disorders analyzes 97 studies with over 41,000 participants. It finds cannabinoids offer short-term symptom relief but lack durable efficacy for abstinence or relapse prevention. The evidence guides…
Cannabinoids in Substance Use Disorders: What a New Systematic Review Actually Found
Cannabinoids and substance use disorders were the focus of a 2026 systematic review spanning 97 studies and nearly 42,000 participants. The review found cannabinoids more often relieved short-term symptoms like craving and withdrawal than they improved…
GLP-1 agonists in addiction therapy – review
GLP-1 receptor agonists show promise in reducing alcohol consumption and cravings, as well as supporting nicotine abstinence. However, more research is needed for stimulant use disorders.
Cannabis in PTSD Treatment: Meta-Analysis of Trauma-Focused Care
This meta-analysis examines cannabis use PTSD treatment outcomes in patients with co-occurring substance use disorders. Trauma-focused treatments remain effective regardless of cannabis use. Cannabis use does not appear to undermine treatment…
Cannabis Use Disorder Carries Greater Psychiatric Risk in Adolescents Than Adults, Johns Hopkins Study Finds
A Johns Hopkins study highlights cannabis use disorder adolescent psychiatric risk as significantly greater than in adults. The research shows age-dependent differences in psychiatric outcomes. These findings emphasize the need for tailored risk…
Neurologic Complications of Drug and Alcohol Use.
A comprehensive clinical review identifies emerging neurologic complications across substance classes, with particular attention to potential cannabis-stroke associations. The review provides neurologists with systematic approaches for recognizing…
Cannabinoid Clinical Trials: Mental Health Evidence
Clinical Takeaway Clinical Takeaway: Current randomized controlled trial evidence does not demonstrate established efficacy or safety of cannabinoids as primary treatment for mental disorders or substance use disorders. Existing research gaps mean…
Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.
A large cohort study of US veterans found GLP-1 receptor agonists substance use disorder prevention benefits compared to other diabetes medications. This BMJ research suggests potential neurobiological effects beyond metabolic control, though causation…
Association of Cannabis Use Disorder Versus Other Substance Use Disorders With Psychiatric Conditions: A Propensity-Matched Retrospective Cohort Analysis.
This study examines the association cannabis use disorder psychiatric conditions compared to other substance use disorders. Researchers used a propensity-matched retrospective cohort analysis. The findings highlight differences in mental disorder risks…
Clinical Evidence on PTSD Trauma-Focused Treatment and Cannabis
Clinical evidence shows that PTSD trauma-focused treatment cannabis use does not significantly reduce the efficacy of evidence-based PTSD protocols. Trauma-focused treatments remain effective for patients with co-occurring cannabis and substance use…